Brisbane, Australia
Vaxxas, founded in 2011, is a pioneering company in the Biotechnology, Health Care, and Medical Devices sectors, headquartered in Australia. The company is revolutionizing vaccine delivery with its innovative, needle-free technology, designed to enhance the performance of current and next-generation vaccines. This technology could redefine vaccine administration globally, providing an opportunity to rethink vaccine efficacy and accessibility.
As of August 2023, Vaxxas secured a $4.00M grant from the prestigious Wellcome Trust, indicating strong market confidence and the potential for significant impact in the healthcare industry. Vaxxas is well-positioned to leverage this funding to advance its technology and address critical healthcare needs, making it a compelling prospect for investors seeking to make a transformative impact in the medical field.
